Top

Published in:

01-02-2009 | Original Article

Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b

Authors: Carlo Lazzaro, Cosetta Bianchi, Lucia Peracino, Paola Zacchetti, Antonio Uccelli

Published in: Neurological Sciences | Issue 1/2009

Abstract

New therapeutic options have modified the natural history and health care costs of multiple sclerosis (MS). An epidemiological 25 years-long model-based cost-utility analysis was performed following the Italian National Health Service (INHS) and societal perspectives to compare costs and quality-adjusted life years of treatment with Interferon β-1b (IFNB-1b) from diagnosis of clinically isolated syndrome (CIS) versus treating at subsequent conversion to clinically definite MS (CDMS). Among patients treated (untreated) with IFNB-1b from CIS diagnosis, 40,420 (43,700) converted to CDMS after 25 years; the estimated cumulative probability of converting to CDMS during the first 3 years was 72.90% (84.94%) (P < 0.0001). Early treatment with IFNB-1b is highly cost-effective for the INHS (incremental cost-effectiveness ratio: Euros 2,574.94) and dominant from the societal viewpoint. Sensitivity analyses confirmed the base case findings. Early treatment with IFNB-1b delays conversion to CDMS in CIS patients and might be a “good value for money” health care programme.

McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913–919PubMedCrossRef

Amato MP, Battaglia MA, Caputo D et al M for the Mu S. I. C. Study Group (2002) The cost of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 249:152–163PubMedCrossRef

Miller DH (2003) Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 326:526–527CrossRef

Kobelt G, Berg J, Lindgren P et al (2006) Costs and quality of multiple sclerosis in Italy. Eur J Health Econ 7:545–554

Jacobs LD, Beck RW, Simon JH, The Champs StudyGroup (2000) Intramuscular interferon beta 1-a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898–904PubMedCrossRef

Filippi M, Rovaris M, Inglese M et al (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364:1463–1464CrossRef

Kappos L, Polman CH, Freedman MS et al for the BENEFIT Study Group (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249PubMedCrossRef

Chilcott J, McCabe C, Tappenden P et al on behalf of the Cost Effectiveness of Multiple Sclerosis Therapies Study Group (2003) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 326:522–526PubMedCrossRef

Attena F (2004) Epidemiologia e valutazione degli interventi sanitari. Piccin, Padova, pp 151–190

10.

McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127PubMedCrossRef

11.

Tintoré M, Rovira A, Río J et al (2003) New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60:27–30PubMedCrossRef

12.

Young TA (2005) Estimating mean total costs in the presence of censoring. A comparative assessment of methods. Pharmacoeconomics 23:1229–1242PubMedCrossRef

13.

Pfeifer PE, Bang H (2005) Non-parametric estimation of mean customer lifetime value. Journal of Interactive Marketing. doi:10.1002/dir.20049

14.

Glick HA, Doshi JA, Sonnad SA, Polsky D (2007) Economic evaluation in clinical trials. Oxford University Press, Oxford, pp 21–22; 115–132

15.

Rice GPA (2001) The use of betaseron in treatment of MS. ENS, Berlin

16.

Compston A, McDonald I, Noseworthy J, Lassmann H, Miller D, Smith K, Wekerle H, Confavreux C (2005) McAlpine’s multiple sclerosis, 4th edn. Elsevier, Amsterdam

17.

Associazione Italiana Sclerosi Multipla (2000) Sclerosi multipla in Italia. Associazione Italiana Sclerosi Multipla, Genova, p 9

18.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMed

19.

Holmes BA, Madgwick T, Bates D (1995) The cost of MS. Br J Med Econ 8:181–193

20.

Kobelt G, Jönsson L, Fredrickson S et al (2001) Cost-utility analysis of interferon β-1b in the treatment of different types of multiple sclerosis. Stockholm School of Economics, SSE/EFI Working Papers on Economics and Finance, Stockholm, No 459

21.

Gold MR, Siegel JE, Russel LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York

22.

Drummond MF, Schulper MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford

23.

Pittock SJ, Mayr WT, McClelland RL et al (2004) Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 62:601–606PubMed

24.

Ministero della Sanità (1999) Nomenclatore tariffario delle protesi. Elenco N. 1: Nomenclatore tariffario delle prestazioni sanitarie protesiche. Ministero della Sanità, Roma

25.

Ministero della Sanità (1996) Decreto ministeriale n. 150 del 22 Luglio 1996. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio sanitario nazionale e relative tariffe. Supplemento ordinario alla Gazzetta Ufficiale n. 216 del 14 Settembre 1996, Serie generale. Istituto Poligrafico e Zecca di Stato, Roma

26.

Presidente della Repubblica (2000) Decreto del Presidente della Repubblica 28 luglio 2000, n. 270. Regolamento di esecuzione dell’accordo collettivo nazionale per la disciplina dei rapporti con i medici di medicina generale. Supplemento ordinario n. 165/L alla Gazzetta Ufficiale n. 230 del 2 Ottobre 2000, Serie Generale. Istituto Poligrafico e Zecca dello Stato, Roma

27.

Conferenza Permanente per i Rapporti tra lo Stato le Regioni e le Province Autonome di Trento e Bolzano (2005) Tariffa Unica Convenzionale per le prestazioni di assistenza ospedaliera. Regole e tariffe valide per l’anno 2006. Available via http://www.ministerosalute.it. Accessed 25 Jun 2007

28.

Schering SpA (2006) Internal data validation by Hospital Survey Project-TNS Healthcare. Schering S.p.A, Segrate

29.

Masson-OEMF (2006) L’Informatore Farmaceutico 2005. Masson-OEMF, Milano

30.

Agenzia Italiana del Farmaco, Direzione Generale-Ministero della Salute (2006) Osservatorio Nazionale sull’Impiego dei Medicinali. L’uso dei Farmaci in Italia. Rapporto nazionale anno 2005. Available via http://www.agenziafarmaco.it. Accessed 25 Jun 2007

31.

De Pietro C (2005) Gestire il personale nelle aziende sanitarie italiane. McGraw-Hill, Milano, pp 353–365

32.

Decision Resources. Cognos Study #3 (2006) Multiple sclerosis. Decision Resources Inc., Waltham, pp 42, 48–50

33.

Sistema Statistico Nazionale-Istituto Nazionale di Statistica (2006) Compendio Statistico Italiano. Available via www.istat.it/Anumital/Astatset/prez.htm. Accessed 4 Feb 2007

34.

Attanasio E, Bruzzi P, Capri S et al (1999) Raccomandazioni per la conduzione degli studi di farmacoeconomia: la Guida GISF. Mecosan 29:65–72

35.

Pagano M, Gauvreau K (2003) Fondamenti di biostatistica, 2nd edn. Idelson-Gnocchi, Napoli, pp 199–216;361–378

36.

Briggs AH, Gray AM (1999) Handling uncertainty when performing economic evaluation of health care interventions. Health Technol Assess 3:1–134PubMed

37.

ISIS Research. ISIS Research MS Monitors. US Phase 4 & Europe Phase 13 Results. US and Europe ISIS Research, 2004

38.

Good PI (2006) Resampling methods. A practical guide to data analysis, 3rd edn. Birckhäuser, Boston

39.

Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman and Hall, New York

40.

Briggs A, Fenn P (1998) Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 7:723–740PubMedCrossRef

41.

Briggs AH (2001) Handling uncertainty in economic evaluation. In: Drummond M, McGuire A (eds) Economic evaluation in health care: merging theory with practice. Oxford University Press, Oxford, pp 172–214

42.

Briggs AH, O’Brien BJ, Blackhouse G (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 23:377–401PubMedCrossRef

43.

Willan AR, Briggs AH (2006) Statistical analysis of cost-effectiveness data. Wiley, Chichester, pp 51–57CrossRef

44.

Fenwick E, O’Brien BJ, Briggs A (2004) Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 13:405–415PubMedCrossRef

45.

Fenwick E, Marshall DA, Levy AR et al (2006) Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 6:52–59PubMedCrossRef

46.

O’Hagan A, Stevens JW (2002) The probability of cost-effectiveness. BMC Medical Research Methodology 2. Available via http://www.biomedcentralcom/1471-2288/2/5. Accessed 22 Oct 2007

47.

Lin DY, Feuer EJ, Etzioni R et al (1997) Estimating medical costs from incomplete follow-up data. Biometrics 53:419–434PubMedCrossRef

48.

Bang H, Tsiatis AA (2000) Estimating medical costs with censored data. Biometrika 87:329–343CrossRef

49.

Russo P, Capone A, Paolillo A et al (2004) Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Invest 24:409–420CrossRef

50.

Flachenecker P, Rieckmann P (2004) Health outcomes in multiple sclerosis. Curr Opin Neurol 17:257–261PubMedCrossRef

51.

Messori A, Santarlasci B, Trippoli S et al (2003) Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. PharmacoEconomics—Italian Research Articles 5:53–67

52.

Mark DB, Hlatky MA, Califf RM et al (1995) Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 332:1418–1424PubMedCrossRef

Title: Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b
Authors: Carlo Lazzaro
Cosetta Bianchi
Lucia Peracino
Paola Zacchetti
Antonio Uccelli
Publication date: 01-02-2009
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 1/2009
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-009-0015-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Ipsilateral ptosis as main feature of tuberothalamic artery infarction

Neuropsychological assessment in myasthenia gravis

Trigeminal neuralgia as initial symptom of paramedian tentorial meningioma

Italian multicentre study of peroneal mononeuropathy: multiperspective follow-up

Long-term experience with continuous duodenal levodopa–carbidopa infusion (Duodopa): report of six patients

An atypical case of spontaneous intracranial hypotension